Steven Frey
24Patents
7h-index
18Co-inventors
66Inventor score
Filing activity: Oct 3, 1995 → Jun 5, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5679564A | Methods for producing enhanced antigenic campylobacter bacteria and vaccines | Emerging Cross-Sectional Technologies | 29 | Expired |
| US5869066A | Vaccine containing a campylobacter bacterium having an enhanced antigenic property | Emerging Cross-Sectional Technologies | 16 | Expired |
| US9464131B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 14 | Active |
| US9051362B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 14 | Active |
| US5681736A | Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same | Emerging Cross-Sectional Technologies | 12 | Expired |
| US10087239B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 12 | Active |
| US5897475A | Vaccines comprising enhanced antigenic helicobacter spp. | Emerging Cross-Sectional Technologies | 10 | Expired |
| US6083683A | Methods for detecting shigella bacteria or antibodies to shigella bacteria with an immunoassay | Emerging Cross-Sectional Technologies | 7 | Expired |
| US6051416A | Methods for producing enhanced antigenic Helicobacter sp. | Emerging Cross-Sectional Technologies | 7 | Expired |
| US5858352A | Vaccine containing a Shigella bacterium having an enhanced antigenic property | Emerging Cross-Sectional Technologies | 4 | Expired |
| US6077678A | Methods for detecting Campylobacter bacteria or antibodies to Campylobacter bacteria with an immunoassay | Emerging Cross-Sectional Technologies | 3 | Expired |
| US11319362B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 2 | Active |
| US5976525A | Method for producing enhanced antigenic enteric bacteria | Emerging Cross-Sectional Technologies | 1 | Expired |
| US8609101B2 | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US9920111B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US11584789B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10865234B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US12312396B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US12410243B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
| US10239934B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US12018067B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10407493B2 | Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity | Chemistry; Metallurgy | 0 | Active |
| US10836811B2 | Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody | Chemistry; Metallurgy | 0 | Active |
| US11845789B2 | Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.